Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC
Amivantamab plus Chemotherapie bei japanischen Patient:innen mit NSCLC und EGFR-Exon-20-Insertions
Cancer Science · 2025-11 · 116 (11) · 3139-3148
DOI: 10.1111/cas.70180 ↗Auf einen Blick
In der japanischen Subpopulation der Phase-3-Studie PAPILLION verlängerte Amivantamab plus Chemotherapie das progressionsfreie Überleben gegenüber Chemotherapie allein. Das Sicherheitsprofil entsprach dem der Gesamtpopulation.
Fragestellung
Wie wirksam und sicher ist Amivantamab plus Chemotherapie im Vergleich zu Chemotherapie allein bei japanischen Patient:innen mit lokal fortgeschrittenem oder metastasiertem NSCLC und EGFR-Exon-20-Insertionsmutation?
Methode
Subgruppenanalyse der offenen randomisierten Phase-3-Studie PAPILLION; 1:1-Randomisierung zu Amivantamab plus Carboplatin/Pemetrexed oder Chemotherapie allein; primärer Endpunkt PFS nach verblindeter zentraler Prüfung.
Ergebnisse
34 japanische Patient:innen (19 vs. 15). Medianes PFS 15,5 Monate (95 %-KI 8,0, NE) mit Amivantamab plus Chemotherapie vs. 5,6 Monate (95 %-KI 3,0, 7,0) mit Chemotherapie allein; HR 0,22 (95 %-KI 0,09, 0,53).
Schlussfolgerung der Autor:innen
Die Wirksamkeits- und Sicherheitsdaten in dieser japanischen Subpopulation waren mit der Gesamtpopulation konsistent und unterstützen den First-Line-Einsatz von Amivantamab plus Chemotherapie in diesem Setting.
Kernaussagen
- Medianes PFS: 15,5 vs. 5,6 Monate
- HR 0,22 (95 %-KI 0,09, 0,53)
- 2 von 19 Patient:innen brachen wegen unerwünschter Ereignisse ab
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Science, online erschienen am 08.09.2025. Verfasst von Satoru Kitazono und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Affairs, At Janssen Pharmaceutical K.K, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (EGFR Exon 20ins) are the third most common mutations in non‐small cell lung cancer (NSCLC) and are associated with a poorer prognosis and resistance to conventional EGFR‐tyrosine kinase inhibitors. This subpopulation analysis of the open‐label phase 3 trial (PAPILLION) evaluates the efficacy and safety of amivantamab–chemotherapy versus chemotherapy among Japanese patients with locally advanced or metastatic NSCLC with EGFR Exon 20ins mutation ( ClinicalTrials.gov , NCT04538664). Patients were randomized 1:1 to either intravenous amivantamab plus carboplatin/pemetrexed chemotherapy or chemotherapy alone. The primary endpoint was progression‐free survival (PFS) by blinded independent central review; the secondary endpoints included objective response rate, duration of response, PFS after first subsequent therapy, overall survival, and safety. The overall population ( n = 308) included 34 Japanese patients (amivantamab–chemotherapy, n = 19; chemotherapy, n = 15). Median PFS was 15.5 (95% CI 8.0, NE) months with amivantamab–chemotherapy compared with 5.6 (95% CI 3.0, 7.0) months (HR = 0.22 [0.09, 0.53]) for chemotherapy alone. Improvements in secondary endpoints were also greater in the amivantamab–chemotherapy arm than the chemotherapy arm. The predominant adverse events associated with amivantamab–chemotherapy were reversible hematologic and EGFR‐related toxic effects; 2 of 19 patients discontinued all study agents due to treatment‐emergent adverse events. Efficacy and safety results in this Japanese subpopulation were consistent with those in the overall population and support the first‐line use of amivantamab–chemotherapy in this setting. Early identification of patients with EGFR Exon 20ins mutations, preferably with more sensitive next‐generation sequencing‐based methods, is important to ensure appropriate patient access to amivantamab–chemotherapy. Trial Registration: ClinicalTrials.gov , NCT04538664.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Affairs, At Janssen Pharmaceutical K.K, Tokyo, Japan.
- Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
- Department of Respiratory Medicine, NHO Himeji Medical Center, Hyogo, Japan.
- Respiratory Center, Matsusaka Municipal Hospital, Mie, Japan.
- Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
- Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
ORCID-Profile: Satoru Kitazono, Hidetoshi Hayashi
Zitieren
APA
Kitazono, S., Ono, A., Kawamura, T., Hataji, O., Tanaka, H., Matsumoto, S., Watanabe, N., Nagashima, H., Oki, M., Takahashi, M., Anazawa, T., Shirai, T., Yamashita, A., Wortman-Vayn, H., Bhattacharya, A., Agrawal, T., Baig, M., Knoblauch, R. E., & Hayashi, H. (2025). Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC. Cancer Science, 116(11), 3139-3148. https://doi.org/10.1111/cas.70180
Vancouver
Kitazono S, Ono A, Kawamura T, Hataji O, Tanaka H, Matsumoto S, et al. Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC. Cancer Science. 2025;116(11):3139-3148. doi:10.1111/cas.70180
BibTeX
@article{Kitazono2025,
author = {Kitazono, Satoru and Ono, Akira and Kawamura, Tetsuji and Hataji, Osamu and Tanaka, Hiroshi and Matsumoto, Shingo and Watanabe, Naohiro and Nagashima, Hiromi and Oki, Masahide and Takahashi, Michiko and Anazawa, Tomoko and Shirai, Takahiro and Yamashita, Aimi and Wortman-Vayn, Honeylet and Bhattacharya, Archan and Agrawal, Trishala and Baig, Mahadi and Knoblauch, Roland E and Hayashi, Hidetoshi},
title = {Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC},
journal = {Cancer Science},
year = {2025},
volume = {116},
number = {11},
pages = {3139--3148},
doi = {10.1111/cas.70180}
}
EUVIMED